News
The company reported a net loss attributable to common stockholders of $5.7 million, or $1.99 per share, for the three months ended June 30, 2025, compared to a net loss attributable to common ...
Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – ...
Focus on including foods high in calories, protein, and nutrients into your loved one’s diet when they are experiencing ...
With the field of HER2-positive breast cancer evolving rapidly, how will practice change in the clinic after the recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results